DE60045720D1 - Behandlung von Krebs beim Menschen mit ET743 - Google Patents

Behandlung von Krebs beim Menschen mit ET743

Info

Publication number
DE60045720D1
DE60045720D1 DE60045720T DE60045720T DE60045720D1 DE 60045720 D1 DE60045720 D1 DE 60045720D1 DE 60045720 T DE60045720 T DE 60045720T DE 60045720 T DE60045720 T DE 60045720T DE 60045720 D1 DE60045720 D1 DE 60045720D1
Authority
DE
Germany
Prior art keywords
humans
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045720T
Other languages
German (de)
English (en)
Inventor
Esteban Cvltkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean Louis Misset
Chris Twelves
Hoff Daniel D Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of DE60045720D1 publication Critical patent/DE60045720D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DE60045720T 1999-05-13 2000-05-15 Behandlung von Krebs beim Menschen mit ET743 Expired - Lifetime DE60045720D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
DE60045720D1 true DE60045720D1 (de) 2011-04-21

Family

ID=27546594

Family Applications (4)

Application Number Title Priority Date Filing Date
DE60045720T Expired - Lifetime DE60045720D1 (de) 1999-05-13 2000-05-15 Behandlung von Krebs beim Menschen mit ET743
DE122008000013C Pending DE122008000013I1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60036826T Expired - Lifetime DE60036826T2 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60030554T Active DE60030554T8 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE122008000013C Pending DE122008000013I1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60036826T Expired - Lifetime DE60036826T2 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60030554T Active DE60030554T8 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1716853B9 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN1360503A (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE375795T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE60045720D1 (enExample)
DK (3) DK1702618T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1702618T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
HK1244713A1 (zh) * 2016-02-04 2018-08-17 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
BR112022020812A2 (pt) 2020-04-15 2022-11-29 Ever Valinject Gmbh Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
JP2562162B2 (ja) * 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
AU746713B2 (en) * 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU758100B2 (en) * 1998-04-06 2003-03-13 Board Of Trustees Of The University Of Illinois, The Semi-synthetic ecteinascidins
JP4583598B2 (ja) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
DK1280809T3 (da) 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidinderivater
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) * 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
CA2583464A1 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
PT1702618E (pt) 2008-01-11
LU91418I2 (fr) 2008-05-13
BR0010531A (pt) 2002-06-04
FR08C0013I2 (fr) 2009-10-30
HUP0201187A2 (en) 2002-09-28
SI1716853T1 (sl) 2011-10-28
IL146434A (en) 2008-03-20
SI1176964T1 (sl) 2007-02-28
EP1716853A2 (en) 2006-11-02
DE60030554T8 (de) 2008-01-10
PT1176964E (pt) 2007-01-31
IL146434A0 (en) 2002-07-25
JP5777562B2 (ja) 2015-09-09
NO2008005I1 (no) 2008-06-09
EP1716853B9 (en) 2011-09-28
NO2008005I2 (enExample) 2010-09-27
CA2373794C (en) 2005-10-11
NO20015516D0 (no) 2001-11-12
CY1105818T1 (el) 2011-02-02
PT1716853E (pt) 2011-05-12
CN1360503A (zh) 2002-07-24
US20070275942A1 (en) 2007-11-29
DK1176964T3 (da) 2007-01-15
CY1112753T1 (el) 2016-02-10
CN1679631A (zh) 2005-10-12
AU777417B2 (en) 2004-10-14
TR200103819T2 (tr) 2002-04-22
MXPA01011562A (es) 2002-07-30
CA2373794A1 (en) 2000-11-23
EP1702618A3 (en) 2006-12-27
EP1702618A2 (en) 2006-09-20
LU91418I9 (enExample) 2019-01-02
WO2000069441A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
AU2005200180B9 (en) 2008-05-29
CY2008007I2 (el) 2009-11-04
EP1702618B1 (en) 2007-10-17
DE60036826D1 (de) 2007-11-29
HUS1500001I1 (hu) 2016-08-29
PL352931A1 (en) 2003-09-22
SK287580B6 (sk) 2011-03-04
MY164077A (en) 2017-11-30
JP2012149095A (ja) 2012-08-09
DE60030554T2 (de) 2007-09-13
HU229866B1 (en) 2014-10-28
ES2272279T3 (es) 2007-05-01
DK1702618T3 (da) 2008-02-25
AU2005200180B2 (en) 2007-12-13
SI1702618T1 (sl) 2008-02-29
EP1716853B1 (en) 2011-03-09
EP1716853A3 (en) 2006-11-15
ES2294756T3 (es) 2008-04-01
DE60036826T2 (de) 2008-08-28
NL300337I1 (nl) 2008-05-01
EP1176964B8 (en) 2007-10-10
KR20020019914A (ko) 2002-03-13
NL300337I2 (nl) 2008-09-01
FR08C0013I1 (enExample) 2008-05-30
NZ515423A (en) 2004-04-30
DE122008000013I1 (de) 2008-08-07
CZ20014081A3 (cs) 2002-11-13
PL198185B1 (pl) 2008-06-30
CZ301482B6 (cs) 2010-03-17
EP1176964A1 (en) 2002-02-06
CN100477993C (zh) 2009-04-15
CY2008007I1 (el) 2009-11-04
JP2002544231A (ja) 2002-12-24
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
DK1716853T3 (da) 2011-06-27
ATE375795T1 (de) 2007-11-15
NO20015516L (no) 2002-01-11
ATE338552T1 (de) 2006-09-15
NO324564B1 (no) 2007-11-19
ATE500830T1 (de) 2011-03-15
UA74782C2 (uk) 2006-02-15
CY1107143T1 (el) 2010-07-28
HUP0201187A3 (en) 2002-11-28
US8119638B2 (en) 2012-02-21
BG65680B1 (bg) 2009-06-30
AR028476A1 (es) 2003-05-14
EP1176964B1 (en) 2006-09-06
SK16442001A3 (sk) 2002-03-05
AU4597500A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE60045720D1 (de) Behandlung von Krebs beim Menschen mit ET743
DE69737793D1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
FI955911A7 (fi) Pyratsolopyrimidinonit impotenssin hoidossa
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
FI970990A7 (fi) Syövän toteaminen ja hoito
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
NO992069D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
EP1085892A4 (en) VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
NO20002189D0 (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
NO20002804L (no) Konjugater som kan anvendes ved behandling av prostatakreft
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
DE69828228D1 (de) Zitrusfruchtessig und Herstellungsverfahren
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
EP1225919A4 (en) TREATMENT OF CANCER